key: cord-0051843-z619mat7
authors: Rong, Zhihui; Mo, Luxia; Pan, Rui; Zhu, Xiaofang; Cheng, Hongbin; Li, Maojun; Yan, Lubiao; Lang, Yujie; Zhu, Xiaoshan; Chen, Liping; Xia, Shiwen; Han, Jun; Chang, Liwen
title: Bovine surfactant in the treatment of pneumonia-induced–neonatal acute respiratory distress syndrome (NARDS) in neonates beyond 34 weeks of gestation: a multicentre, randomized, assessor-blinded, placebo-controlled trial
date: 2020-10-21
journal: Eur J Pediatr
DOI: 10.1007/s00431-020-03821-2
sha: 9597dba91b677529a7f205eb71fb2c0e897ff9ae
doc_id: 51843
cord_uid: z619mat7

Neonatal acute respiratory distress syndrome (NARDS) reflects pulmonary surfactant dysfunction, and the usage of bovine surfactant (Calsurf) supplement may therefore be beneficial. To determine whether bovine surfactant given in NARDS can improve oxygenation and survival rate, we conducted a multicenter, randomized trial between January 2018 and June 2019, and we compared Calsurf treatment to controls in neonates with pneumonia accompanied by NARDS. Neonates who met the Montreux criteria definition of NARDS were included, and those with congenital heart and lung malformations were excluded. Primary outcomes were oxygenation index (OI) after Calsurf administration, and secondary outcomes were mortality, and duration of ventilator and oxygen between the two groups, and also other morbidities. Cumulatively, 328 neonates were recruited and analyzed, 162 in the control group, and 166 in the Calsurf group. The results shows that OI in the Calsurf group were significantly lower than that in the control group at 4 h (7.2 ± 2.7 and 11.4 ± 9.1, P = 0.001); similarly, OI in the Calsurf group were significantly lower than in the control group at 12 h ( 7.5 ± 3.1 and 11.2 ± 9.2, P = 0.001). Mortality and duration of ventilator support or oxygen use between the two groups were not significantly different. Conclusion: Calsurf acutely improved OI immediately after administration in pneumonia-induced NARDS; although, we observed no significant decrease in mortality, duration of ventilator or oxygen, or major morbidity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00431-020-03821-2) contains supplementary material, which is available to authorized users.

In 2015, the Pediatric Acute Lung Injury (ALI) Consensus Conference 2015 (PALICC) developed diagnostic criteria for acute respiratory distress syndrome (ARDS) in children ranging from infants to teenagers. ARDS is a generalized inflammatory response of the lung to catastrophic events of various pulmonary and non-pulmonary origins, such that children with ARDS often exhibit high mortality [1] . It is generally accepted that the degree of hypoxemia predicts outcome, mortality in children with a PaO 2 /FiO 2 ratio lower than 100 greater than 50%. Another outcome predictor is ventilation support, reflected in mean airway pressure [2] . There are many ventilation strategies being evaluated in the pediatric age group to prevent barotrauma and volutrauma, including high-frequency oscillatory ventilation (HFV), inhaled nitric oxide, extracorporeal membrane oxygenation (ECMO), and surfactant treatment [3] .

In 2017, De Luca et al. [4] proposed the Monteux definition for neonatal acute respiratory distress syndrome (NARDS). But information regarding NARDS-especially treatment strategies-is still limited. Chinese clinicians performed several single-center clinical studies that were published in Chinese journals [16, 17] , finding that Calsurf (Shuanghe Pharmaceutics, Beijing, China) supplement benefited infants with NARDS. However, to our knowledge, there is still paucity of evidence from randomized controlled trials to support the application of surfactant in NARDS. Thus, we performed a randomized, multicenter, assessor-blinded, placebo-controlled trial in patients with NARDS induced by pneumonia to better understand whether oxygenation and survival rate improve after exogenous surfactant administration in cases of mild, moderate, and severe NARDS.

The present study was a randomized control trial (ChiCTR-OPC-17011351) conducted at 12 level 3 neonatal intensive care units between January 2018 and June 2019. The distribution of the 12 centers is depicted in Supplementary Data, and the study protocol was approved by the review boards of these institutes. Informed consent was obtained from a parent or guardian before enrollment.

Entry criteria included (1) a gestational age above 34 weeks and (2) an acute onset of pneumonia no later than 1 week of age. The definition of neonates pneumonia was according to Dell'Orto's report: presented respiratory distress with either patchy infiltrates and/or irregular opacities at chest radiogram or loss of aeration/consolidations on lung ultrasound and both of the following criteria: (1) at least one of the following: risk factors for perinatal infection (chorioamnionitis, maternal fever, bacterial colonization, rupture of membranes for more than 18 h); (2) at least one of the following: serum Creactive protein >10 mg/L, or serum procalcitonin beyond reference values according to hours of life [24] ; (3) absence of congenital heart disease that would explain the edema (such as ductus arteriosus with pulmonary overflow if no acute pulmonary hemorrhage existed-echocardiography was needed to verify the origin of the edema); (4) oxygenation deficit expressed as OI, mild NARDS at 4-7.9 , moderate NARDS at 8-15.9 , and severe NARDS at ≥ 16. Exclusion criteria included RDS, TTN, or any congenital anomaly capable of causing a primary, current, acute respiratory condition. These inclusion and exclusion criteria depict a newborn population completely fulfilling the Montreux criteria for the diagnosis of NARDS [4] .

Neonates were assigned randomly to control or Calsurf groups: random numbers were generated by a computer program and randomization performed using serially numbered, opaque, sealed envelopes that were opened by research personnel after obtaining parental consent. According to protocol, a second intervention was performed 12 h later if the oxygenation index remained higher than 7.

Although blinding of the clinicians was not possible due to the nature of the intervention, assessors who did data collection and measured OI were blinded to the type of treatment administered.

Calsurf is extracted from lung lavage of calves. Total phosphate lipids are 35 mg/ml, with 59% of DPPC; 0.78 mg/m l of surfactant B and 1.74 mg/ml of surfactant C. The recommended dosage is 100 mg/kg. For surfactant administration, the position of the endotracheal tube was determined by the length of the tube at the lip, the symmetry of breath sounds, and the symmetric rising of the chest wall. Natural surfactant (Calsurf; Shuanghe Pharmaceutics, China) was refrigerated at − 10°C before use and solubilized in 1.5 mL of sterile water to form a suspension. The suspension was warmed to approximately 37°C and then a catheter was used to administer the surfactant near the proximal end of the endotracheal at a dose of 100 mg/kg. The infants were disconnected with the tube and manual bag positive pressure ventilation (maintained for approximately 5 min) was exerted during surfactant administration, followed by mechanical ventilation. The control group received a volume equivalent air bolus in the endotracheal tube, followed by manual bag positive pressure ventilation (maintained for approximately 5 min).

Primary outcomes were OI at 4, 12, and 24 h after administration of Calsurf. OI was based on pre-ductal arterial PaO 2 in all infants included. Secondary outcomes were mortality, duration of ventilator or oxygen, and major morbidity issues, including incidence of pneumothorax, pulmonary hypertension, stage 2 or greater necrotizing enterocolitis (NEC), grade 3/4 intracranial ventricular hemorrhage (IVH), or periventricular leukomalacia (PVL).

We conducted a stratified study, and OI and mortality were compared between pre-specified subgroups.

Small-for-gestational-age (SGA) was defined as birth weight below the 10th percentile at a particular gestational week in Fenton growth chart [5] .

The preliminary data from our center indicated that the OI was 11 in controls, and we hypothesized that treatment would decrease OI to 7. We therefore required 130 cases and 130 controls to be able to reject the null hypothesis that the exposure rates for cases and controls were equal, with a probability (power) 0.8. The type I error probability associated with the test of our null hypothesis was 0.05. We anticipated an attrition of 10% of infants, and therefore needed to enroll 145 patients were needed in each group.

We used the statistical software packages SPSS for Windows version 19 for data analyses. Continuously distributed variables were expressed as mean ± one standard deviation, and categorical variables were summarized as numbers and percentages. We used analysis of variance (ANOVA) after analyzing for homogeneity analysis of variance, and this was followed by post hoc testing. The nonparametric rank-sum test (Kruskal-Wallis test) was used if the variance was not homogenous. We performed a multivariate linear regression analysis to rule out confounding factors. Candidate variables with a p value < 0.1 on univariate analysis and considered clinically relevant were included in multivariable model. Variables for inclusion were carefully chosen, given the number of events available. All the eligible variables were entered into the model. Results are presented as beta and confidence intervals (CI 95%) and p values. Adjusted R 2 is presented to evaluate the goodness of fit evaluation. P < 0.05 was considered to show a significant difference.

A total of 345 neonates met the inclusion criteria and provided consent: 172 of these neonates were randomly assigned to the control group and 173 were randomly assigned to the Calsurf treatment group. Ten infants died in the control group and seven infants died in the Calsurf group, and therefore 162 controls and 166 treatments were ultimately analyzed (Fig.  1) . Baseline characters and antenatal factors of the two groups were similar, although P values for prenatal steroid usage and gestational age showed a tendency toward significance (Table 1 ). In the Calsurf treatment group, patients received an average of 3 doses (1 to 8) of surfactant.

The results between-group patients comparisons shows that OI in the Calsurf group were significantly lower than in the control group at 4 h (7.2 ± 2.7 and 11.4 ± 9.1, P = 0.001), similarly, OI in the Calsurf group were significantly lower than in the control group at 12 h (7.5 ± 3.1 and 11.2 ± 9.2, P = 0.001) (Fig. 2) .

We conducted a stratified study, and the results are shown in Fig. 2 . Infants with NARDS were stratified into three categories according to oxygenation deficit expressed as OI: mild NARDS, 4-7.9; moderate NARDS, 8-15.9 ; and severe NARDS, ≥ 16. The cases of mild, moderate, and severe NARDS in this study were 105, 113, and 110, respectively, and Calsurf administration significantly decreased the OI in all 3 groups, especially in moderate and severe cases (Fig. 2) . We performed a multivariate linear regression analysis of OI at 4 and 12 h using subgroup partitioning, and the results are presented in Table 2 . When we brought the variables (prenatal steroids, gestational age, and intervention) into the regression model to remove the confounding factors, we observed that only Calsurf treatment was a dependent protective factor in reducing OI.

The overall mortality rate in NARDS was approximately 5%, with 10 deaths in control group and 7 deaths in Calsurf group. Duration of ventilation or oxygen and length of hospital stay did not differ between the two groups (P > 0.05), and we did not observe a difference in the incidence of pneumothorax, pulmonary hypertension, NEC (stage 2 or greater), grade 3/4 IVH, or PVL (Table 3 ).

ARDS is defined by radiographic diagnosis of diffuse bilateral alveolar infiltrates, the degree of hypoxemia, lung function, and histopathology, and it occurs in all age groups. ARDS and respiratory distress syndrome (RDS) in neonates show the same clinical characteristics, and differentiation of the two syndromes is justified on the basis of pathophysiologic and etiologic differences [6] . NARDS was not defined in neonates until 2017, when De Luca et al. published an article describing the biologic and pathophysiologic features of NARDS as being similar to those seen in older children and adults with ARDS [4] .

We only focused on pneumonia-induced ARDS which defines ARDS more accurately especially for late preterm infants. It is generally accepted that the degree of hypoxemia and ventilator support (as reflected by mean airway pressure) can predict outcome [2] , and we therefore stratified infants with NARDS into three categories based on OI. This definition stipulates OI thresholds of 4.0-7.9 for mild NARDS, 8.0-15.9 for moderate NARDS, and 16.0 or higher for severe NARDS [7, 8] . Calsurf treatment improves OI but has no effect on survival rate

Many therapies are currently being evaluated in pediatric patients, including lung-protective ventilation strategies, inhaled nitric oxide, extracorporeal membrane oxygenation (ECMO), and surfactant treatment [3] . NARDS is biologically characterized by qualitative or quantitative surfactant dysfunction that affects proteins and phospholipids, and the afflicted neoantes show extensive inflammation of their pulmonary tissues [9, 10] . Two studies of recombinant surfactant protein in NARDS indicated improvement in oxygenation but without an effect on survival [11, 12] , and a follow-up analysis of the study suggested patients with severe NARDS from pneumonia had an improvement in a 28-day survival after surfactant administration [12] . Calsurf is extracted from newborn bovine lungs, is produced in China, and has been used here for several years. Chinese clinical trials by Kong et al. showed that Calsurf supplementation improved pulmonary status when given to preterm infants with severe RDS [13, 14] , and Cogo P et al. reported that compared to treatment with 200 mg/ kg of porcine surfactant , 100 mg/kg of porcine surfactant increased the risk of reuse. However, it is not possible to use such high doses of bovine surfactants; this is one of the major reasons of the inferiority of bovine compared to porcine surfactant [15] [16] [17] . Regarding to the selection of drug dosage, Chinese [18, 19] . Thus, we used the higher dose of bovine surfactants in the current study, and showed that the OI in the Calsurf group was significantly lower than in the control group after surfactant administration. In the stratified study, the results were equivalent in mild, moderate, and severe cases of NARDS, and these results are somewhat consistent with those reported by Wilson and Luo, who demonstrated that surfactant acutely improved oxygenation and significantly decreased mortality in children and adolescents with ARDS [20, 21] . The mortality rate of infants with NARDS was proximately 5% in our study, while severe NARDS manifested the highest mortality rate (15%). The rate of complications did not differ between the two groups, and some investigators have suggested that the mortality rate in children is lower than in adults-ranging between 18% and 27% [22] . Wong reported that mortality was approximately 30.3% in his study of pediatric patients with ARDS [23] , while in our study we found that the mortality rate in infants with NARDS was much lower than in older children. There have no differences in the secondary outcomes as these are extremely multifactorial and it is difficult that surfactant can change this.

To the best of our knowledge, this is the first study to describe the effects of surfactant in treating NARDS. However, there are limitations to this study. First, for preterm infants under 34 weeks of gestation, clinicians have some difficulties to the differential definition of neonatal RDS and NARDS, thus to standardize the definition for all the 12 NICUs, preterm babies under 34 weeks of gestation were not included in our study. The mortality rate recorded herein, therefore, might not reflect the overall NARDS. Second, there are two kinds of surfactants in Chinese market: bovine surfactant and porcine surfactant. Exclusively bovine surfactants were used in this study; however, the results could not be applied to other surfactants. Thirdly, because there is lack of phase I/II studies about Calsurf dose range, we do not know whether 100 mg/kg is the best dose for treating NARDS, thus more dose ranging studies for Calsurf are needed. Moreover, the lack of the information about SNAPPE-II score is another limitation, since it is a better indicator to compare the severity of the disease between the two groups. In addition, not every center can provide inhaled NO and ECMO, so these two treatments were not assessed in the current study.

Calsurf acutely improved oxygenation immediately after administration in pneumonia-induced NARDS at a gestational age beyond 34 week. However, we recommend that surfactant should be used cautiously in pneumonia-induced NARDS.

) Pathogen screening and prognostic factors in children with severe ARDS of pulmonary origin

Pathophysiology and management of acute respiratory distress syndrome in children

The Montreux definition of neonatal ARDS: biological and clinical background behind the description of a new entity

Validating the weight gain of preterm infants between the reference growth curve of the fetus and the term infant

Hyaline membrane in the neonatal lung

Differences in clinical characteristics and therapy of neonatal acute respiratory distress syndrome (ARDS) and respiratory distress syndrome (RDS): a retrospective analysis of 925 cases

for the Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress yndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference

Surfactant alteration and replacement in acute respiratory distress syndrome

A role for phospholipase A2 in ARDS pathogenesis

Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome

A search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute)

Bovine surfactant replacement therapy in neonates of less than 32 weeks' gestation: a multicenter controlled trial of prophylaxis versus early treatment in China-a pilot study

High-risk factors of respiratory distress syndrome in term neonates: a retrospective case-control study

Pharmacokinetics and clinical predictors of surfactant redosing in respiratory distress syndrome

Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants

Porcine vs bovine surfactant therapy for preterm neonates with RDS: systematic review with biological plausibility and pragmatic meta-analysis of respiratory outcomes

Clinical evaluation of Calsurf in treating full-term neonatal respiratory distress syndrome

Different dosage of bovine surfactant in treating respiratory distress syndrome in late preterm infants

Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial

Treatment with bovine surfactant in severe acute respiratory distress syndrome in children: a randomized multicenter study

Progress and perspectives in pediatric acute respiratory distress syndrome

Risk stratification in pediatric acute respiratory distress syndrome: a multicenter observational study

Cell count analysis from nonbronchoscopic bronchoalveolar lavage in preterm infants

Acknowledgments We thank Dr Cong Liu for the review of the statistical analysis in this manuscript preparation. 1 

Authors' contributions Dr. Zhihui Rong conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript.Dr. Luxia Mo designed the data collection instruments, drafted the initial manuscript, and reviewed and revised the manuscript.Dr. Rui Pan designed the data collection instruments, drafted the initial manuscript, and reviewed and revised the manuscript.Dr. Xiaofang Zhu designed the data collection instruments, and reviewed and revised the manuscript.Dr. Hongbin Cheng designed the data collection instruments, and reviewed and revised the manuscript.Dr. Maojun Li designed the data collection instruments, and reviewed and revised the manuscript.Dr. Lubiao Yan designed the data collection instruments, and reviewed and revised the manuscript.Dr. Yujie Lang designed the data collection instruments, and reviewed and revised the manuscript.Dr. Xiaoshan Zhu designed the data collection instruments, and reviewed and revised the manuscript.Dr. Liping Chen designed the data collection instruments, and reviewed and revised the manuscript.Dr. Shiwen Xia designed the data collection instruments, and reviewed and revised the manuscript.Dr. Jun Han designed the data collection instruments, and reviewed and revised the manuscript.Profs. Liwen Chang helped in the study design, preparation of data collection instrument, reviewed all the data and performed their interpretation, drafted the manuscript, and significantly reviewed and revised it. All authors approved the final version manuscript.Funding This study was supported by the research clinicians of Huazhong University of Science and Technology (Second batch) and China International Medical Foundation 2018.

Conflict of interest The authors declare that they have no conflicts of interest.Ethical approval All procedures described herein were followed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5) .Informed consent Informed consent was obtained from all individual participants included in the present study.